Peficitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Peficitinib (also known as ASP015K) is a JAK inhibitor in Phase II of development for RA by Astellas. It is expected to be used in patients with moderate to severe RA who have had an inadequate response to MTX and/or one or more biologic agents, such as the anti-TNFs.
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Peficitinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Peficitinib for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Peficitinib performance.
- Obtain sales forecast for Peficitinib from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK and Japan).